Imatinib Crescent Pharma (Imatinib)

Imatinib binds to the ATP‑binding pocket of BCR‑ABL, c‑KIT and PDGFR tyrosine kinases, preventing their activation. This blocks downstream signaling pathways that promote cell proliferation and survival, leading to apoptosis of malignant cells and inhibition of tumor angiogenesis.

The exact dose and schedule of Imatinib Crescent Pharma are determined by the prescribing clinician based on the specific indication, disease stage, patient weight, renal and hepatic function, and concomitant therapies. Healthcare professionals should follow the latest clinical guidelines and product labeling.

Safety data for Imatinib in pregnancy and lactation are limited. The drug may cause fetal harm, and it is generally advised to avoid use unless the potential benefit justifies the risk. Breastfeeding while on Imatinib is not recommended because the medication can be excreted in milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements) and the necessary import documentation.

Imatinib was the first BCR‑ABL inhibitor and remains a standard of care for CML and GIST. Newer agents such as dasatinib, nilotinib or sunitinib may offer activity against certain resistant mutations, but Imatinib retains a well‑characterized safety profile and is often preferred as first‑line therapy in many treatment guidelines.

Imatinib Crescent Pharma tablets should be stored at ambient temperature, below 25 °C, in the original packaging to protect from moisture and light. Do not store in bathrooms or near heat sources, and keep out of reach of children.

The medication is taken orally, usually once daily, with or without food as directed by the prescriber. Swallow the tablet whole with a full glass of water; do not crush or chew unless specifically instructed.

Serious adverse events include severe neutropenia, hepatotoxicity, cardiotoxicity (reduced left‑ventricular ejection fraction), fluid retention leading to pleural or pericardial effusion, and rare anaphylactic reactions. Patients should be monitored regularly for blood counts, liver enzymes and cardiac function.

Imatinib is contraindicated in patients with known hypersensitivity to the drug or any of its excipients, and in those with severe hepatic impairment. Caution is also advised for individuals with pre‑existing cardiac disease, uncontrolled infections, or who are pregnant without a clear therapeutic justification.